BACKGROUND: HIV infection and antiretroviral therapy are associated with dyslipidemia, but the association between regional body fat and lipid levels is not well described. METHODS: Multivariable linear regression analyzed the association between magnetic resonance imaging-measured regional adipose tissue and fasting lipids in 284 HIV-infected and 129 control women. RESULTS: Among African Americans, HIV-infected women had higher triglyceride (116 vs. 83 mg/dL; P < 0.001), similar high-density lipoprotein (HDL; 52 vs. 50 mg/dL; P = 0.60), and lower low-density lipoprotein (LDL; 99 vs. 118 mg/dL; P = 0.008) levels than controls. Among whites, HIV-infected women had higher triglyceride (141 vs. 78 mg/dL; P < 0.001), lower HDL (46 vs. 57 mg/dL; P < 0.001), and slightly lower LDL (100 vs. 107 mg/dL; P = 0.059) levels than controls. After adjustment for demographic and lifestyle factors, the highest tertile of visceral adipose tissue (VAT) was associated with higher triglyceride (+85%, 95% confidence interval [CI]: 55 to 121) and lower HDL (-9%, 95% CI: -18 to 0) levels in HIV-infected women; the highest tertile of leg subcutaneous adipose tissue (SAT) was associated with lower triglyceride levels in HIV-infected women (-28%, 95% CI: -41 to -11) and controls (-39%, 95% CI: -5 to -18). After further adjustment for adipose tissue, HIV infection remained associated with higher triglyceride (+40%, 95% CI: 21 to 63) and lower LDL (-17%, 95% CI: -26 to -8) levels, whereas HIV infection remained associated with lower HDL levels (-21%, 95% CI: -29 to -12) in whites but not in African Americans (+8%, 95% CI: -2 to 19). CONCLUSIONS: HIV-infected white women are more likely to have proatherogenic lipid profiles than HIV-infected African American women. Less leg SAT and more VAT are important factors associated with adverse lipid levels. HIV-infected women may be at particular risk for dyslipidemia because of the risk for HIV-associated lipoatrophy.
BACKGROUND:HIV infection and antiretroviral therapy are associated with dyslipidemia, but the association between regional body fat and lipid levels is not well described. METHODS: Multivariable linear regression analyzed the association between magnetic resonance imaging-measured regional adipose tissue and fasting lipids in 284 HIV-infected and 129 control women. RESULTS: Among African Americans, HIV-infectedwomen had higher triglyceride (116 vs. 83 mg/dL; P < 0.001), similar high-density lipoprotein (HDL; 52 vs. 50 mg/dL; P = 0.60), and lower low-density lipoprotein (LDL; 99 vs. 118 mg/dL; P = 0.008) levels than controls. Among whites, HIV-infectedwomen had higher triglyceride (141 vs. 78 mg/dL; P < 0.001), lower HDL (46 vs. 57 mg/dL; P < 0.001), and slightly lower LDL (100 vs. 107 mg/dL; P = 0.059) levels than controls. After adjustment for demographic and lifestyle factors, the highest tertile of visceral adipose tissue (VAT) was associated with higher triglyceride (+85%, 95% confidence interval [CI]: 55 to 121) and lower HDL (-9%, 95% CI: -18 to 0) levels in HIV-infectedwomen; the highest tertile of leg subcutaneous adipose tissue (SAT) was associated with lower triglyceride levels in HIV-infectedwomen (-28%, 95% CI: -41 to -11) and controls (-39%, 95% CI: -5 to -18). After further adjustment for adipose tissue, HIV infection remained associated with higher triglyceride (+40%, 95% CI: 21 to 63) and lower LDL (-17%, 95% CI: -26 to -8) levels, whereas HIV infection remained associated with lower HDL levels (-21%, 95% CI: -29 to -12) in whites but not in African Americans (+8%, 95% CI: -2 to 19). CONCLUSIONS:HIV-infected white women are more likely to have proatherogenic lipid profiles than HIV-infected African American women. Less leg SAT and more VAT are important factors associated with adverse lipid levels. HIV-infectedwomen may be at particular risk for dyslipidemia because of the risk for HIV-associated lipoatrophy.
Authors: Wei Shen; ZiMian Wang; Haiying Tang; Stanley Heshka; Mark Punyanitya; Shankuan Zhu; Jianbo Lei; Steven B Heymsfield Journal: Obes Res Date: 2003-02
Authors: Frank J Palella; Stephen R Cole; Joan S Chmiel; Sharon A Riddler; Barbara Visscher; Adrian Dobs; Carolyn Williams Journal: Clin Infect Dis Date: 2004-03-01 Impact factor: 9.079
Authors: G H Hughes; G Cutter; R Donahue; G D Friedman; S Hulley; E Hunkeler; D R Jacobs; K Liu; S Orden; P Pirie Journal: Control Clin Trials Date: 1987-12
Authors: M van der Valk; J J Kastelein; R L Murphy; F van Leth; C Katlama; A Horban; M Glesby; G Behrens; B Clotet; R K Stellato; H O Molhuizen; P Reiss Journal: AIDS Date: 2001-12-07 Impact factor: 4.177
Authors: K Mulligan; V W Tai; H Algren; D I Abrams; R J Leiser; J C Lo; M Schambelan Journal: J Acquir Immune Defic Syndr Date: 2001-04-15 Impact factor: 3.731
Authors: Joel E Gallant; Schlomo Staszewski; Anton L Pozniak; Edwin DeJesus; Jamal M A H Suleiman; Michael D Miller; Dion F Coakley; Biao Lu; John J Toole; Andrew K Cheng Journal: JAMA Date: 2004-07-14 Impact factor: 56.272
Authors: Phyllis C Tien; Stephen R Cole; Carolyn Masters Williams; Rui Li; Jessica E Justman; Mardge H Cohen; Mary Young; Nancy Rubin; Michael Augenbraun; Carl Grunfeld Journal: J Acquir Immune Defic Syndr Date: 2003-12-15 Impact factor: 3.731
Authors: Grace A Lee; Tara Seneviratne; Mustafa A Noor; Joan C Lo; Jean-Marc Schwarz; Francesca T Aweeka; Kathleen Mulligan; Morris Schambelan; Carl Grunfeld Journal: AIDS Date: 2004-03-05 Impact factor: 4.177
Authors: Rebecca Scherzer; Wei Shen; Steven B Heymsfield; Cora E Lewis; Donald P Kotler; Mark Punyanitya; Peter Bacchetti; Michael G Shlipak; Carl Grunfeld Journal: Obesity (Silver Spring) Date: 2010-06-10 Impact factor: 5.002
Authors: Carl Grunfeld; Michael Saag; Joseph Cofrancesco; Cora Elizabeth Lewis; Richard Kronmal; Steven Heymsfield; Phyllis C Tien; Peter Bacchetti; Michael Shlipak; Rebecca Scherzer Journal: AIDS Date: 2010-07-17 Impact factor: 4.177
Authors: Phyllis C Tien; Michael F Schneider; Christopher Cox; Mardge Cohen; Roksana Karim; Jason Lazar; Mary Young; Marshall J Glesby Journal: AIDS Date: 2010-11-27 Impact factor: 4.177
Authors: Carl Grunfeld; Donald P Kotler; Donna K Arnett; Julian M Falutz; Steven M Haffner; Paul Hruz; Henry Masur; James B Meigs; Kathleen Mulligan; Peter Reiss; Katherine Samaras Journal: Circulation Date: 2008-06-19 Impact factor: 29.690
Authors: Jordan E Lake; Quynh T Vo; Lisa P Jacobson; Ned Sacktor; Eric N Miller; Wendy S Post; James T Becker; Frank J Palella; Ann Ragin; Eileen Martin; Cynthia A Munro; Todd T Brown Journal: Antivir Ther Date: 2015-03-26
Authors: Judith S Currier; Claudia Martorell; Olayemi Osiyemi; Michael T Yin; Robert Ryan; Guy De La Rosa; Joseph Mrus Journal: AIDS Patient Care STDS Date: 2011-06 Impact factor: 5.078
Authors: Marisela Noorhasan; Daniel R Drozd; Carl Grunfeld; Joseph O Merrill; Greer A Burkholder; Michael J Mugavero; James H Willig; Amanda L Willig; Karen L Cropsey; Kenneth H Mayer; Aaron Blashill; Matthew Mimiaga; Mary E McCaul; Heidi Hutton; Geetanjali Chander; William C Mathews; Sonia Napravnik; Joseph J Eron; Katerina Christopoulos; Rob J Fredericksen; Robin M Nance; Joseph Chris Delaney; Paul K Crane; Michael S Saag; Mari M Kitahata; Heidi M Crane Journal: AIDS Res Hum Retroviruses Date: 2017-02-16 Impact factor: 2.205
Authors: Julie A Womack; Rebecca Scherzer; Stephen R Cole; Kristopher Fennie; Ann B Williams; Margaret Grey; Howard Minkoff; Kathryn Anastos; Mardge H Cohen; Phyllis C Tien Journal: J Acquir Immune Defic Syndr Date: 2009-12 Impact factor: 3.731